Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy

AIM: To investigate the clinical effects of traditional Chinese medicine, Si Ling San, on acute central serous chorioretinopathy(CSC). <p>METHODS: We retrospectively analyzed the clinical data of 48 patients(48 eyes)with CSC, among whom 24 were given oral Si Ling San(as treatment group)and the...

Full description

Bibliographic Details
Main Author: Hu-Lin Luo
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2017-09-01
Series:Guoji Yanke Zazhi
Subjects:
Online Access:http://ies.ijo.cn/cn_publish/2017/9/201709045.pdf
_version_ 1818847871497142272
author Hu-Lin Luo
author_facet Hu-Lin Luo
author_sort Hu-Lin Luo
collection DOAJ
description AIM: To investigate the clinical effects of traditional Chinese medicine, Si Ling San, on acute central serous chorioretinopathy(CSC). <p>METHODS: We retrospectively analyzed the clinical data of 48 patients(48 eyes)with CSC, among whom 24 were given oral Si Ling San(as treatment group)and the other 24 did not receive any treatment(control group). The baseline and 1 or 3mo follow-up data for the best corrected visual acuity(BCVA), central macular thickness(CMT)and maximum height of subretinal fluid(SRF)were collected and then compared between the two groups. <p>RESULTS: BCVA of the treatment group was not statistically different from the baseline level at 1mo(<i>P</i>>0.05), but it was significantly improved at 3mo(<i>P</i><0.05). BCVA was better at 3mo than that at 1mo(<i>P</i><0.05). In the control group, however, no significant improvement of BCVA was found at 1 or 3mo compared with baseline(both <i>P</i>>0.05). The BCVA of the two groups was not significantly different at baseline and 1 and 3mo follow-up(all <i>P</i>>0.05). In the treatment group CMT and SRF at 1 and 3mo were significantly lower than baseline(both <i>P</i><0.05). CMT and SRF at 3mo were significantly lower than that at 1 month(both <i>P</i><0.05). In the control group, CMT and SRF at 1mo were not different from baseline level(both <i>P</i>>0.05), while they were significantly decreased at 3mo follow-up(both <i>P</i><0.05). CMT and SRF at 3mo were significantly lower than that at 1mo(both <i>P</i><0.05). In addition, CMT and SRF of the treatment group at both 1 and 3mo were statistically lower than that of the control group(all <i>P</i><0.05). <p>CONCLUSION: This study preliminary suggest that oral Si Ling San has the potential to treat acute CSC. But further trials are warranted to study its role in improving the visual function, shortening the duration and reducing the recurrence of CSC.
first_indexed 2024-12-19T06:08:20Z
format Article
id doaj.art-897e5796ccb942c2b8b70166edb1b33a
institution Directory Open Access Journal
issn 1672-5123
1672-5123
language English
last_indexed 2024-12-19T06:08:20Z
publishDate 2017-09-01
publisher Press of International Journal of Ophthalmology (IJO PRESS)
record_format Article
series Guoji Yanke Zazhi
spelling doaj.art-897e5796ccb942c2b8b70166edb1b33a2022-12-21T20:33:05ZengPress of International Journal of Ophthalmology (IJO PRESS)Guoji Yanke Zazhi1672-51231672-51232017-09-011791773177610.3980/j.issn.1672-5123.2017.9.45Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathyHu-Lin Luo0Department of Ophthalmology, Hospital of Traditional Chinese Medicine of Fufeng County, Baoji 722200, Shaanxi Province, ChinaAIM: To investigate the clinical effects of traditional Chinese medicine, Si Ling San, on acute central serous chorioretinopathy(CSC). <p>METHODS: We retrospectively analyzed the clinical data of 48 patients(48 eyes)with CSC, among whom 24 were given oral Si Ling San(as treatment group)and the other 24 did not receive any treatment(control group). The baseline and 1 or 3mo follow-up data for the best corrected visual acuity(BCVA), central macular thickness(CMT)and maximum height of subretinal fluid(SRF)were collected and then compared between the two groups. <p>RESULTS: BCVA of the treatment group was not statistically different from the baseline level at 1mo(<i>P</i>>0.05), but it was significantly improved at 3mo(<i>P</i><0.05). BCVA was better at 3mo than that at 1mo(<i>P</i><0.05). In the control group, however, no significant improvement of BCVA was found at 1 or 3mo compared with baseline(both <i>P</i>>0.05). The BCVA of the two groups was not significantly different at baseline and 1 and 3mo follow-up(all <i>P</i>>0.05). In the treatment group CMT and SRF at 1 and 3mo were significantly lower than baseline(both <i>P</i><0.05). CMT and SRF at 3mo were significantly lower than that at 1 month(both <i>P</i><0.05). In the control group, CMT and SRF at 1mo were not different from baseline level(both <i>P</i>>0.05), while they were significantly decreased at 3mo follow-up(both <i>P</i><0.05). CMT and SRF at 3mo were significantly lower than that at 1mo(both <i>P</i><0.05). In addition, CMT and SRF of the treatment group at both 1 and 3mo were statistically lower than that of the control group(all <i>P</i><0.05). <p>CONCLUSION: This study preliminary suggest that oral Si Ling San has the potential to treat acute CSC. But further trials are warranted to study its role in improving the visual function, shortening the duration and reducing the recurrence of CSC.http://ies.ijo.cn/cn_publish/2017/9/201709045.pdfcentral serous chorioretinopathytraditional Chinese medicineSi Ling Sanvisual acuitycentral macular thicknesssubretinal fluidsubretinal fluid
spellingShingle Hu-Lin Luo
Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy
Guoji Yanke Zazhi
central serous chorioretinopathy
traditional Chinese medicine
Si Ling San
visual acuity
central macular thickness
subretinal fluid
subretinal fluid
title Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy
title_full Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy
title_fullStr Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy
title_full_unstemmed Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy
title_short Clinical efficacy of Si Ling San in treatment of acute central serous chorioretinopathy
title_sort clinical efficacy of si ling san in treatment of acute central serous chorioretinopathy
topic central serous chorioretinopathy
traditional Chinese medicine
Si Ling San
visual acuity
central macular thickness
subretinal fluid
subretinal fluid
url http://ies.ijo.cn/cn_publish/2017/9/201709045.pdf
work_keys_str_mv AT hulinluo clinicalefficacyofsilingsanintreatmentofacutecentralserouschorioretinopathy